This just in… we’re still waiting for guidance from the FDA on social media. Actually, we AREN’T waiting. We can’t afford to wait. The fact is, the social media train has left the station, and we at Edelman have been actively working with our clients in the regulated space to help them navigate the medium without official guidance.
To add more fuel to the fire, WEGO Health has updated their original survey of their Health Activists (
Despite the Internet being around for quite some time, the FDA has never issued specific guidance to pharmaceutical companies on how they can communicate about and market their products online, instead stating that the existing guidelines for print and television should be applied. However, there is difficulty in interpretation: if providing the prescribing information on the back of a print ad is acceptable, is that equal to having the information one click away? Instead of official guidance and directives, we learn what is okay – and what doesn’t fly – through…
PSFK, a trends research and innovation company, recently prepared a report for Unicef titled “The Future of Health” in which they explore how advances in technology are impacting healthcare for the masses, particularly in less developed markets. PSFK also invited several leading advertising and design agencies to imagine solutions for healthcare in emerging countries by responding…
As we wait for the official word from the FDA on how the DDMAC guidelines should be applied to the digital space, we can learn how the FDA is interpreting the use of social media for promotional activities through their warning letters. Novartis Pharmaceuticals Corporation (an Edelman client, though not for this particular promotion) recently received a warning letter…
Contact Us Copyright © 2008-2011 Edelman Digital, a Daniel J. Edelman Company. All rights reserved.